Exabis Library
Welcome to the e-CCO Library!
P670: Identification of two additional susceptibility loci for Crohn's disease in Koreans
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P670: Therapeutic efficacy and economic impact of half sulfasalazine therapy for refractory ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P670: “What Matters To You?” – How do patient views compare with a patient experience framework and UK national standards of care?
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P671 Natural history and clinical outcomes of patients with ulcerative colitis who are intolerant to 5-aminosalicylic acid agents: A multi-centre cohort study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P671: Calprotectin does not add accuracy to PRO2 for prediction of continuous clinical response in moderate-to-severe ulcerative colitis patients treated with golimumab
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P671: Early suppression of the serological macrophage activity biomarker VICM, and not suppression of CRP, predicts the response to infliximab in Crohn's disease patients
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P671: Effect of genetic polymorphisms in the folate pathway on the efficacy and safety of methotrexate in Crohn’s disease.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P671: Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands: a retrospective observational study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P671: Occurrence and clinical impact of eosinophilic esophagitis in a large cohort of children with Inflammatory Bowel Disease.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P671: Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: Results from the UniStar study long-term extension
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P672 The escalation of therapy or intervention (ETI) calculator for ulcerative colitis: does it have the potential to help outpatient capacity meet demand?
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P672: A tertiary multicenter cohort of patients with chronic intestinal pseudo-obstruction and Crohn’s disease: a rare association with a high prevalence of monogenic disorders.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P672: Biologic therapy for Inflammatory Bowel Disease in Poland in 2020: nationwide data.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P672: Drug therapy and monitoring for inflammatory bowel diseases: preliminary data from a multi-centre investigation in Asia
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P672: Number needed to treat to achieve clinical response at week 8 along with response or remission at week 52 with ustekinumab treatment vs. placebo from the phase 3 UNITI Crohn’s disease studies, by population
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P672: Surgical and anti-TNFs combined therapy prevents Crohn's perianal fistula recurrence: a systematic review and meta-analysis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P672: Switching out of class or to another anti-TNF agent is the most effective strategy in IBD patients with immunogenicity against anti-TNF antibodies
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P673 Strategy of selecting anti-TNF agent in patients with Crohn’s disease: A multi-centre retrospective cohort study by the Osaka gut forum
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P673: Achievement of tight control based on serum C-reactive protein and albumin correlated with better outcomes in Japanese Crohn’s disease patients treated with biologics
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P673: Intra-abdominal collections in Crohn's disease: outcomes following anti-TNF therapy
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM